IBD98-M is an oral, multi-layer coated pellet combines HA and mesalamine for targeted colonic delivery.
• Mode of Action: Forms a resorbable HA barrier over inflamed mucosa while delivering mesalamine locally
• Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation
Inflammatory bowel diseases (IBD), which consists of ulcerative colitis (UC) and Crohn's disease (CD), is are characterized by chronic inflammation of the gastrointestinal tract in genetically susceptible individuals exposed to environmental risk factors that affect 5 million people worldwide.
IBD98-M, a Delayed-Release Capsule, containing mesalamine, and sodium hyaluronate, is being developed by HylMusa™ platform as a combination therapy for treatment of patients with mild to moderate UC. The mechanisms of action of IBD98-M Delayed-Release Capsule is as a combination therapy are to combine the therapeutic effects of mesalamine and a barrier effect of sodium hyaluronate to protect the damaged mucosa. Mesalamine has been widely utilized for decades as an anti-inflammatory agent, in treating mild to moderate active CD and UC. Sodium hyaluronate may act as a protective barrier to the lining of the colon affected by UC, and therefore provides additional therapeutic benefits either by enhancing the efficacy of mesalamine or allowing a reduction of mesalamine dose and its associated toxicity.

CA102N is a dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC, TNBC, and mCRC.
• Clinical Data: Phase I in mCRC showed prolonged PFS, improved DCR, and strong tolerability
• Differentiation: >300 hrs tumor retention, 10x dose reduction with maintained efficacy
Hyaluronic acid (HA), a biocompatible linear polysaccharide, has recently been utilized as a drug delivery vehicle. HA conjugated drugs (HACD) are drug delivery systems for targeted transport of anticancer therapeutics to tumor cells through interaction of HA with the cells CD44 receptor. HA-Conjugated drugs HylTargis™ platform represent a new generation of targeted cancer therapeutics with enhanced anti-tumor efficacy and low undesirable side effects.
Nimesulide, one of the most potent non-steroidal anti-inflammatory drugs (NSAIDs) studied so far in cancer chemotherapy, has been shown to inhibit tumor progression in several in vitro and in vivo studies.
CA102N is the conjugation of HA and a derivative of Nimesulide which not only targets tumor cell surface receptor CD44, but also undergoes enzymatic degradation within the lysosomal compartment eventually resulting in tumor growth inhibition.

A dual-pathway (PI3K/mTOR + MAPK) HA conjugate targeting high-CD44 tumors, including KRAS G12D-mutant PDAC
• ODD application for PDAC; expansion to other tumor types
CA102N is developed under HylTargis™ platform, designed to deliver chemotherapeutic payloads with enhanced specificity, improved tumor penetration, and reduced systemic toxicity in CD44-overexpressing tumors such as pancreatic ductal adenocarcinoma (PDAC)
By utilizing a tailored hyaluronic acid (HA) backbone, CA102N leverages the overexpression of CD44 receptors on tumor cells and tumor-associated stroma to achieve active targeting and selective accumulation in the tumor microenvironment (TME). This approach is particularly suited for stroma-rich, chemoresistant tumors.

CA102N synergy with 5-FU in TNBC model inhibit tumor growth
• 5-FU increases AKT/mTOR activity
• CA102N and CA102N + 5-FU reduce PI3K/Akt/mTOR pathway activity
CA102N is developed under HylTargis™ platform, designed to deliver chemotherapeutic payloads with enhanced specificity, improved tumor penetration, and reduced systemic toxicity in CD44-overexpressing tumors such as triple-negative breast cancer (TNBC)
CA102N addresses enhancing intratumoral payload concentration and modifying local stromal behavior without introducing systemic inflammation or overlapping toxicity

ND108E is a CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer's patients.
• Preclinical Data: Reversal of learning and memory deficits in behavioral models
• Mechanism: Amyloid plaque reduction confirmed by PET imaging; increased spine density and restored ChAT activity
• Status: IND-enabling studies in progress
ND108E is developed by HylNeuro™ platform to target the regular memory formation through dendritic spine remodeling, synapse plasticity to reduce the amyloid beta and Tau protein aggregation. ND108E is a novel conjugated drug with multi-function mechanism of drug and brain delivery system. The preliminary in-vivo data is promising and patent has been filed.

AMD112 is a non-invasive HA-conjugated small molecule therapy designed for wet age-related macular degeneration (wAMD) and other neovascular retinal diseases. Under HylRetinX™ platform, AMD112 enables oral or topical (eyedrop) administration with targeted delivery to the retina through CD44-mediated translocation across the blood-retinal barrier (BRB).
• Efficacy: Demonstrated significant lesion size reduction in a laser-induced CNV model
• Next Steps: Optimization of oral formulation and MOA confirmation underway

HA nanoparticle system is a novel HA-based nanoparticle delivery system for mRNA, siRNA, and nucleic acid therapeutics, developed by HylCaryo™ platform as an alternative to lipid nanoparticles (LNPs) and viral vectors. Designed for CD44-mediated targeting, non-immunogenicity, and barrier penetration, HA nanoparticles enables precise tissue-selective delivery of RNA-based payloads with high safety and formulation flexibility.